Experts: Rena Conti (Boston University) and Marta Wosinska (Brookings)
Ensuring access to safe, high-quality and low-cost medicines has been of concern to patients, medical providers and policymakers. As manufacturers have sought labor and capital efficiencies, including through reductions in supply chain redundancies and offshoring, critical supply chain vulnerabilities have arisen (Conti, Berndt 2019; FDA 2020). The creation and sustainment of high quality, resilient supply chains are further hampered by significant system opacity, especially related to base and intermediate ingredients (NASEM 2022). The Conti-Wosinska team project builds off prior work and has two components: identifying drug supply chains that would benefit from government intervention and assessing the role of technology in making those supply chains more resilient.